- Home
- RIGL vs PNRG Comparison
RIGL vs PNRG Comparison
Compare RIGL & PNRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- PNRG
- Stock Information
- Founded
- RIGL 1996
- PNRG 1973
- Country
- RIGL United States
- PNRG United States
- Employees
- RIGL N/A
- PNRG N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- PNRG Oil & Gas Production
- Sector
- RIGL Health Care
- PNRG Energy
- Exchange
- RIGL Nasdaq
- PNRG Nasdaq
- Market Cap
- RIGL 366.5M
- PNRG 371.2M
- IPO Year
- RIGL 2000
- PNRG N/A
- Fundamental
- Price
- RIGL $17.17
- PNRG $223.12
- Analyst Decision
- RIGL Buy
- PNRG
- Analyst Count
- RIGL 5
- PNRG 0
- Target Price
- RIGL $36.80
- PNRG N/A
- AVG Volume (30 Days)
- RIGL 253.6K
- PNRG 18.1K
- Earning Date
- RIGL 03-04-2025
- PNRG 05-16-2025
- Dividend Yield
- RIGL N/A
- PNRG N/A
- EPS Growth
- RIGL N/A
- PNRG 71.12
- EPS
- RIGL 0.99
- PNRG 23.14
- Revenue
- RIGL $179,278,000.00
- PNRG $210,064,000.00
- Revenue This Year
- RIGL $14.19
- PNRG N/A
- Revenue Next Year
- RIGL $13.10
- PNRG N/A
- P/E Ratio
- RIGL $17.17
- PNRG $9.85
- Revenue Growth
- RIGL 54.71
- PNRG 88.03
- 52 Week Low
- RIGL $7.48
- PNRG $98.55
- 52 Week High
- RIGL $29.82
- PNRG $243.49
- Technical
- Relative Strength Index (RSI)
- RIGL 34.02
- PNRG 64.29
- Support Level
- RIGL $17.01
- PNRG $220.06
- Resistance Level
- RIGL $19.97
- PNRG $234.17
- Average True Range (ATR)
- RIGL 1.01
- PNRG 7.31
- MACD
- RIGL -0.29
- PNRG 2.02
- Stochastic Oscillator
- RIGL 10.65
- PNRG 68.63
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About PNRG PrimeEnergy Resources Corporation
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and provide well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.